New 1 H-pyrazole-4-carboxamides with antiplatelet activity

Archiv der Pharmazie

Volumn 342, Issue 1, 2009, Pages 27-33

  Rehse, Klaus ^a   Kotthaus, Joscha ^b   Khadembashi, Laleh ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

1 H pyrazole 4 carboxamides; ADP; Adrenaline; Antiplatelet properties; PAF antagonism

Indexed keywords

5 (4 CHLOROPHENYLSULFONYLAMINO) 1 PHENYL N (1 PHENYL METHYL 4 PIPERIDINYL) 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (2 ETHYLAMINOETHYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (2 HEXYLAMINOETHYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (2 METHOXYETHYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (2 METHYLAMINOETHYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (2 PHENYLAMINOETHYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (3 CYCLOHEXYLAMINOPROPYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; 5 (4 CHLOROPHENYLSULFONYLAMINO) N (3 METHOXYPROPYL) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; APAFANT; N (2 BUTYLAMINOETHYL) 5 (4 CHLOROPHENYLSULFONYLAMINO) 1 PHENYL 1H PYRAZOLE 4 CARBOXAMIDE; PHENTOLAMINE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; AMIDE; PYRAZOLE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; HUMAN; IC 50; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; CELL CULTURE; CHEMISTRY; DRUG EFFECT; SYNTHESIS; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; AMIDES; CELLS, CULTURED; EPINEPHRINE; HUMANS; INHIBITORY CONCENTRATION 50; PLATELET ACTIVATING FACTOR; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549096728     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200800181     Document Type: Article

References (11)

1. K. Märschenz, K. Rehse, Arch. Pharm. Chem. Life Sci. 2006, 339, 115-122.
2. A. K. Yildiz, K. Rehse, J.-P. Stasch, E. Bischoff, Arch. Pharm. Pharm. Med. Chem. 2004, 337, 311-316.
3. A. Cwiklicki, K. Rehse, Arch. Pharm. Pharm. Med. Chem. 2004, 337, 156 -163.
4. K. Bethge, H. H. Pertz, K. Rehse, Arch. Pharm. Chem. life Sci. 2005, 338, 78-86.
5. K. Rehse, J. Steege, Arch. Pharm. Chem. life Sci. 2005, 338, 539-547.
6. K. Rehse, H. Gonska, Arch. Pharm. Chem. life Sci. 2005, 338, 590-597.
7. M. Johnsen, K. Rehse, H. Pertz, J.-P. Stasch, E. Bischhoff, Arch. Pharm. Med. Chem. 2003, 336, 1 - 7.
8. K. Rehse, T. Baselt, Arch. Pharm. Chem. Life Sci. Accepted for publication.
9. G. V. R. Born, Nature (London) 1962, 194, 927-929.
10. F. Seuter, Haemostasis 1976, 5, 85-95.
11. C. A. Lipinski, F. Lombardo, B. W. Domini, P. J. Feeney, Adv. Drug Deliv. Rev. 1997, 23, 3-25.